Project Grant R21DA063767
Award Date
7/15/25
Completion Date
6/30/27
Dollars Obligated
$251K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Woodbridge, IN 47408, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will support a research project entitled "Optimizing Developmental Outcomes in Early Childhood After Neonatal Opioid Withdrawal Syndrome." The $180,059 award, effective August 1, 2024, will fund a 5-year longitudinal study to assess the independent and moderating effects of positive childhood experiences (PCEs) and adverse childhood experiences...
The National Institute on Drug Abuse (NIDA) awarded The Washington University a 3-year, $2,337,729 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to study the impact of prenatal opioid exposure on placental and fetal brain development. The project, titled "The Opioid in Pregnancy: Imaging of Oxygenation, Inflammation, and Development in Brain & Placenta" (OPIOID BPP), aims to define the longitudinal effects of prenatal opioid exposure on...
This $2,267,819 Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Abuse and Addiction Research Programs) will fund research by the University of Washington to characterize extracellular vesicle (EV) profiles in healthy pregnancies and those complicated by opioid use disorder. The goal is to identify biomarkers in placental EVs and fetal brain/central nervous system EVs that could predict an infant's risk of developing neonatal opioid withdrawal syndrome (NOWS) and...
This federal Project Grant award of $411,800 from the National Institute on Drug Abuse (NIDA)'s Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of Rekovar Inc.'s NeoMonki, a wireless wearable device and AI-driven system for monitoring and assessing Neonatal Abstinence Syndrome (NAS). The funding will enable two phases of research and development: 1) initial data collection, AI algorithm development, and preparation for FDA de novo submission, and 2) clinical trial...
The National Institute on Drug Abuse (NIDA) awarded Magee-Womens Research Institute and Foundation a $3,092,159 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to conduct a multimodal analysis of gestational health and placental injury in opioid-affected pregnancies. The goal is to investigate the direct impact of illicit and prescription opioids on placental development, differentiation, and function, focusing on the critical syncytiotrophoblast and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the CFDA program "Drug Use and Addiction Research Programs" (93.279), will support research to uncover the neurophysiological signatures within the addiction circuitry related to acute opioid use. The $159,711 award, effective January 1, 2025 through December 31, 2029, will leverage a unique ability to directly record local field potentials from awake humans with implanted brain electrodes. This will...
This Project Grant award of $3,011,183 from the National Institute on Drug Abuse (NIDA), under the Drug Abuse and Addiction Research Programs (CFDA 93.279), supports research to investigate the effects of maternal opioid use disorder (OUD) on the placenta-brain axis and associated neurocognitive outcomes in offspring. The University of Kentucky Research Foundation, the prime awardee, will utilize a systems biology approach to integrate phenotypic, functional, and genomic data from the...
This Cooperative Agreement award of $1,278,689 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop an automated Neonatal Pain Monitoring System (NPMS) and pain management protocol to objectively measure and minimize postoperative pain in newborns. The project has two key objectives: 1) Develop and validate AI-driven neonatal pain biomarker signatures and an automated NPMS to continuously...
The National Institutes of Health (NIH) awarded Boston Medical Center Corporation a $2,573,346 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279). The 3-year grant, which commenced on September 1, 2023, will fund a prospective cohort study comparing 100 opioid-exposed pregnancies to 50 non-exposed controls. The study aims to: Compare serial microRNA (miRNA) signatures in opioid-exposed and control pregnancies using maternal plasma and placental tissue samples. The...
The National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), awarded Labsys LLC a $643,948 Project Grant to develop a wearable continuous drug monitoring device for opioid use disorders (CDM-MOUD). The goal is to create a low-cost, pain-free patch that can monitor medication levels in the interstitial fluid and provide real-time insights into the effectiveness of opioid use disorder treatment protocols. In Phase I, Labsys will engineer an...